Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Questcor Pharmaceuticals ( QCOR) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 2.7%. By the end of trading, Questcor Pharmaceuticals rose $3.04 (4.4%) to $72.17 on average volume. Throughout the day, 2,255,898 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 2,403,800 shares. The stock ranged in a price between $68.15-$72.31 after having opened the day at $69.53 as compared to the previous trading day's close of $69.13. Other companies within the Drugs industry that increased today were: Catalyst Pharmaceutical Partners ( CPRX), up 8.6%, ProPhase Labs ( PRPH), up 7.9%, Prana Biotechnology ( PRAN), up 4.8% and Imprimis Pharmaceuticals ( IMMY), up 4.4%.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Questcor Pharmaceuticals has a market cap of $4.2 billion and is part of the health care sector. Shares are up 27.0% year to date as of the close of trading on Wednesday. Currently there are 5 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Venaxis ( APPY), down 15.5%, Akebia Therapeutics ( AKBA), down 12.5%, Celladon ( CLDN), down 12.4% and Ignyta ( RXDX), down 10.8% , were all laggards within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes